Chunxiao Sun, Yuqi Jiang, Changlong Li, Simin Sun, Jiaqi Lin, Wenxue Wang, Luning Zhou, Liping Li, Mudassir Shah, Qian Che, Guojian Zhang, De Wang, Tianjiao Zhu, Dehai Li
Numerous clinical disorders have been linked to the etiology of dysregulated NLRP3 (NACHT, LRR, and PYD domain-containing protein 3) inflammasome activation. Despite its potential as a pharmacological target, modulation of NLRP3 activity remains challenging. Only a sparse number of compounds have been reported that can modulate NLRP3 and none of them have been developed into a commercially available drug. In this research, we identified three potent NLRP3 inflammasome inhibitors, gymnoasins A-C (1-3), with unprecedented pentacyclic scaffolds, from an Antarctic fungus Pseudogymnoascus sp...
June 4, 2024: Angewandte Chemie